Axonics, Inc. (NASDAQ:AXNX) Shares Sold by Creative Planning

Creative Planning trimmed its position in shares of Axonics, Inc. (NASDAQ:AXNX) by 12.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,696 shares of the company’s stock after selling 506 shares during the quarter. Creative Planning’s holdings in Axonics were worth $257,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in AXNX. Edgestream Partners L.P. acquired a new stake in Axonics in the 1st quarter valued at about $605,000. Janus Henderson Group PLC increased its holdings in shares of Axonics by 637.7% in the first quarter. Janus Henderson Group PLC now owns 178,322 shares of the company’s stock valued at $12,298,000 after purchasing an additional 154,149 shares during the last quarter. Gabelli Funds LLC purchased a new position in Axonics during the first quarter worth approximately $12,271,000. Cowen AND Company LLC acquired a new position in Axonics during the second quarter worth $605,000. Finally, Bank of New York Mellon Corp grew its holdings in Axonics by 12.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 218,171 shares of the company’s stock valued at $14,668,000 after buying an additional 23,460 shares in the last quarter. Hedge funds and other institutional investors own 99.48% of the company’s stock.

Axonics Stock Performance

Shares of Axonics stock opened at $70.42 on Friday. The stock has a 50 day moving average of $69.70 and a 200 day moving average of $68.45. The firm has a market capitalization of $3.60 billion, a price-to-earnings ratio of -1,760.06 and a beta of 0.82. Axonics, Inc. has a fifty-two week low of $49.70 and a fifty-two week high of $70.75.

Insider Transactions at Axonics

In other Axonics news, CFO Kari Leigh Keese sold 2,961 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $69.41, for a total value of $205,523.01. Following the transaction, the chief financial officer now owns 40,362 shares of the company’s stock, valued at $2,801,526.42. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 1.85% of the company’s stock.

Analysts Set New Price Targets

Separately, Needham & Company LLC reiterated a “hold” rating on shares of Axonics in a report on Friday. Eight equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Axonics presently has an average rating of “Hold” and an average target price of $71.00.

About Axonics

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.